Many companies along with Gilead have stepped up to the plate making huge, at-risk investments in both R&D and in production to literally help save the world. This came at the expense of diverting precious R&D resources to this effort. In addition, Gilead has stated publicly that it will DONATE 1.5 million doses of remdesivir, enough to treat 140,000 patients at no cost to patients for compassionate use, expanded access and then broader use. Gilead has also provided assurances that access won’t be an issue, leading industry analysts to speculate that remdesivir won’t be a revenue driver for Gilead.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,